Clinical data
Trade names Cardura, others
AHFS/ Monograph
MedlinePlus a693045
Routes of
By mouth (tablets)
ATC code C02CA04 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 65%
Protein binding 98%
Metabolism Liver
Biological half-life 22 hours
CAS Number 74191-85-8 YesY
PubChem (CID) 3157
DrugBank DB00590 YesY
ChemSpider 3045 YesY
UNII NW1291F1W8 YesY
KEGG D07874 YesY
ECHA InfoCard 100.128.642
Chemical and physical data
Formula C23H25N5O5
Molar mass 451.475 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture

Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura and Carduran, is an α1-selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia (BPH).

On February 22, 2005, the US FDA approved an extended release form of doxazosin, to be marketed as Cardura XL.

It is an α1 adrenergic receptor blocker that inhibits the binding of norepinephrine (released from sympathetic nerve terminals) to the α1 receptors on the membrane of vascular smooth muscle cells. The primary effect of this inhibition is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.

Doxazosin and similar medications like prazosin have been found to help reduce the intensity of and/or stop posttraumatic stress disorder night terrors and nightmares. The full explanation for this effect is not understood.

In Egypt, tablet formulation sold as Duracin produced by Biopharm group for research and the drug industry, Dosin by Eipico and Doxazocine by Multi-Apex.


In March 2000, the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study stopped its arm of the trial looking at alpha blockers, because doxazosin was less effective than a simple diuretic, and because patients on doxazosin had a 25% higher rate of cardiovascular disease and twice the rate of congestive heart failure as patients on diuretics.[1] Pfizer, aware of the results before publication, launched a marketing campaign in early 2000, and sales were largely unaffected, despite the dangers highlighted by the study.[2][3]

Doxazosin shows potential for treatment of benign prostatic hyperplasia and erectile dysfunction.[4]

Doxazosin has also shown some efficacy in treating chronic epididymitis.[5]


  1. Piller LB, Davis BR, Cutler JA, et al. (2002). "Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone". Curr Control Trials Cardiovasc Med. 3 (1): 10. doi:10.1186/1468-6708-3-10. PMC 149403Freely accessible. PMID 12459039.
  2. Goldacre, Ben (2012) Bad Pharma How drug companies mislead doctors and harm patients, Fourth Estate, ISBN 0007350740.
  3. Lenzer, J (2003). "Spin doctors soft pedal data on antihypertensives". BMJ: British Medical Journal. 326 (7381): 170. doi:10.1136/bmj.326.7381.170. PMC 1128917Freely accessible.
  4. "Antihypertensive Drugs and Patients With Erectile Dysfunction". Medscape.
  5. Zhou, YC; Xia GS; Xue YY; Zhang XD; Zheng LW; Jin BF (2010–2012). "Kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin for the treatment of chronic epididymitis". Zhonghua Nan Ke Xue (in Chinese). 16 (12): 1143–6. PMID 21348207.
This article is issued from Wikipedia - version of the 9/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.